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Loss of intraepidermal nerve fiber density
during SIV peripheral neuropathy is
mediated by monocyte activation and
elevated monocyte chemotactic proteins
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Abstract
Background: Peripheral neuropathy (PN) continues to be a major complication of human immunodeficiency virus
(HIV) infection despite successful anti-retroviral therapy. Human HIV-PN can be recapitulated in a CD8-depleted,
simian immunodeficiency virus (SIV)-infected rhesus macaque animal model, characterized by a loss of intraepidermal
nerve fiber density (IENFD) and damage to the dorsal root ganglia (DRG). Increased monocyte traffic to the DRG has
previously been associated with severe DRG pathology, as well as a loss in IENFD. Here, we sought to characterize the
molecular signals associated with monocyte activation and trafficking to the DRGs.
Methods: Eleven SIV-infected CD8-depleted rhesus macaques were compared to four uninfected control animals.
sCD14, sCD163, sCD137, regulated on activation normal T cell expressed and secreted (RANTES), and monocyte
chemoattractant protein 1 (MCP-1) were measured in plasma and the latter three proteins were also quantified in DRG
tissue lysates. All SIV-infected animals received serial skin biopsies to measure IENFD loss as well as BrdU inoculations to
measure monocyte turnover during the course of infection. The number of BrdU+ and CD14+ CD16+ peripheral blood
monocytes was determined by flow cytometry. The number of MAC387+, CCR2+, CCR5+, and CD137+ cells in DRG
tissue was quantified by immunohistochemistry.
Results: sCD14, sCD163, MCP-1, and sCD137 increased significantly in plasma from pre-infection to necropsy. Plasma
sCD163 and RANTES inversely correlated with IENFD. Additionally, sCD137 in DRG tissue lysate was elevated with
severe DRG pathology and associated with the recruitment of MAC387+ cells to DRG. Elevated numbers of CCR5+ and
CCR2+ satellite cells in the DRG were found, suggesting a chemotactic role of their ligands, RANTES, and MCP-1 in
recruiting monocytes to the tissue.
Conclusions: We characterized the role of systemic (plasma) and tissue-specific (DRG) monocyte activation and
associated cytokines in the pathogenesis of SIV-PN. We identified sCD163 and RANTES as potential biomarkers for
HIV-PN, as these were associated with a loss of IENFD. Additionally, we identified CD137 signaling to play a role
in MAC387+ cell traffic to DRG and possibly contribute to severe pathology. These studies highlight the role of
monocyte activation and traffic in the pathogenesis of SIV-PN, while identifying specific signaling proteins for
future pharmacological blockade.
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Background
Human immunodeficiency virus peripheral neuropathy
(HIV-PN) continues to be problematic among the HIV-
infected population despite successful use of anti-retroviral
therapy (ART) to reduce plasma viral loads and increase
patient longevity [1]. Distal sensory polyneuropathy (DSP),
a common type of HIV-PN, consists of damage to the dor-
sal root ganglia (DRG) that is associated with loss of distal
axons including small diameter unmyelinated nerve fibers
that project to the skin and are measured by intraepider-
mal nerve fiber density (IENFD) [2–4]. Axonal loss and
damage to the DRG is thought to occur either via direct
neurotoxicity of viral proteins or through indirect mecha-
nisms from chronic immune activation. Application of
HIV viral proteins, Tat, gp120, and Vpr in vitro has re-
sulted in neurotoxicity of DRG neurons [5–7]. However,
neuronal damage can occur in humans with undetectable
viral loads [1], and viral expression in the DRG does not
correlate with pathology severity [8]. Instead, in the SIV
rhesus macaque animal model, we found that monocyte
traffic to the DRG is associated with DRG pathology, as
well as a loss of IENFD [8]. However, the underlying
mechanism of neurodegeneration in vivo has yet to be
fully elucidated.
Monocyte activation is a hallmark of HIV comorbidities
among patients on ART [9–11]. Monocyte and macro-
phage activation, often measured by plasma biomarkers
such as sCD14 and sCD163, has been associated with an
increase risk of cardiovascular disease, HIV-associated
neurocognitive disorders (HAND), renal disease, and
frailty [12–15]. Additionally, a greater rate of monocyte
egress from the bone marrow is associated with faster pro-
gression to AIDS in a CD8-depleted SIV-infected rhesus
macaque model of HIV [16]. Furthermore, the CD14+
CD16+ monocyte population expands during HIV infec-
tion [17–19], and this expansion of activated monocytes is
associated with HAND [18, 20].
Cytokines have a large impact on the nervous system,
in addition to regulating the immune response. DRG
neurons express cytokine receptors on their surfaces, so
they can appropriately respond to cytokines in their en-
vironment [21, 22]. CCR5, the receptor for RANTES
(Regulated on Activation, Normal T cell Expressed and
Secreted)/CCL5, can be expressed on DRG neuronal cell
bodies. gp120 can bind to CCR5 resulting in neuronal
excitation [23]. CCR2, another chemokine receptor
expressed on DRG neurons, can also facilitate neuronal
excitation when it binds to monocyte-chemoattractant-1
(MCP-1/CCL2) [24]. Various rodent models of neuro-
pathic pain have demonstrated that blocking the MCP-
1-CCR2 interaction via neutralizing antibodies or gene
knockout can block pain sensation [25–29]. Neuronal
cell bodies in the DRG can also upregulate inflammatory
cytokines following peripheral nerve injury [30–32].
Thus, cytokines can transmit pain signals from the per-
iphery to the central nervous system (CNS) via interac-
tions with cytokine receptors on DRG neurons [28, 33].
Additionally, MCP-1 and RANTES might increase re-
cruitment of monocytes to the DRG causing further
neuronal damage and activation [21, 34, 35].
Other signaling pathways besides CCR2 and CCR5 are
likely involved in neuronal damage during SIV-DSP.
One potential signaling protein of interest is CD137,
which is a member of TNF superfamily that can be
expressed on T cells, monocytes, and other immune
cells, as well as endothelial cells [36, 37]. CD137 cross-
linking on monocytes induces activation and production
of pro-inflammatory cytokines [38]. CD137 expression
on endothelial cells facilitates migration of monocytes
out of blood vessels and into tissues [37, 39]. Addition-
ally, CD137 reverse signaling is involved in myelopoiesis
[40, 41]. Elevated sCD137 in plasma, a splice variant of
CD137, has been associated with several inflammation-
linked diseases [42–44], but its role in monocyte activa-
tion during HIV infection has not been studied.
We used a CD8-depleted, SIV-infected macaque
model to recapitulate HIV-DSP in humans, where ani-
mals show a loss of IENFD and DRG pathology [45–47].
We have previously demonstrated an influx of activated
MAC387+ macrophages to the DRG as well as an in-
crease in CD163+ macrophages. Importantly, we found
that increased cell traffic was associated with severe
DRG pathology and a greater loss of IENFD [8]. This
study sought to investigate the role of monocyte activa-
tion in HIV-DSP, as well as identify cytokines that are
associated with monocyte activation and neuronal loss
in plasma and in DRG tissue.
Methods
Ethical statement
All animals used in this study were handled in strict
accordance with American Association for Accredit-
ation of Laboratory Animal Care with the approval of
the Institutional Animal Care and Use Committee of
Harvard University and the Institutional Animal Care
and Use Committee of Tulane University.
Animals, viral infection, and CD8 lymphocyte depletion
Fifteen rhesus macaques (Macaca mulatta) were utilized
in this study. Eleven animals were inoculated intraven-
ously with SIVmac251 (a generous gift from Dr. Ronald
Desrosiers, University of Miami). Four uninfected rhesus
macaques served as uninfected controls. All infected ani-
mals were administered 10 mg/kg of anti-CD8 antibody
subcutaneously at day 6 after infection and 5 mg/kg
intravenously at days 8 and 12 after infection in order to
achieve rapid progression to AIDS. The human anti-
CD8 antibody was provided by the NIH Non-human
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Primate Reagent Resource (RR016001, AI040101). SIV-
infected animals were sacrificed at the onset of terminal
AIDS. The development of simian AIDS was determined
post-mortem by the presence of Pneumocystis carinii-as-
sociated interstitial pneumonia, Mycobacterium avium-as-
sociated granulomatous enteritis, hepatitis, lymphadenitis,
and/or adenovirus infection of surface enterocytes in both
small and large intestine. Animals were housed at either
the New England Primate Research Center (NEPRC;
Southborough, MA) or Tulane University’s National Pri-
mate Research Center (TNPRC; Covington, LA) in strict
accordance with standards of the American Association
for Accreditation of Laboratory Animal Care.
Necropsy and histopathology
Animals were necropsied immediately following death,
and representative sections of all major organs were col-
lected, fixed in 10 % neutral-buffered formalin (NBF),
embedded in paraffin, and sectioned at 5 μm. After
deparaffinization in xylene, the tissues were hydrated in
graded alcohols, counterstained with Harris hematoxylin
solution (Sigma-Aldrich) for two minutes, and rinsed
with running water. The slides were then dipped sequen-
tially in acid alcohol (90 % methanol, 5 % sulfuric acid,
5 % acetic acid; Sigma-Aldrich) and ammonia water
(15–20 drops ammonium hydroxide in 250 ml water;
Sigma-Aldrich), rinsing with running water after each,
followed by 80 % alcohol for 2 min and eosin (Sigma-Al-
drich) for 2 min. Tissue sections were then rinsed in
graded alcohols and dehydrated with xylene and
mounted with VectaMount (Vector).
Histopathologic analysis of DRG morphology
H and Estained sections of DRG were evaluated blindly
for histopathologic lesions by a board-certified veterinary
anatomic pathologist (ADM) and scored based on the
presence and severity of infiltrating mononuclear cells,
neuronophagia, and Nageotte nodules as previously de-
scribed [8, 46]. Overall pathology was scored on a previ-
ously validated [8] scale of 1–3 at increments of 0.5 via
the following criteria: (1) Mild: scattered infiltrating
mononuclear cells with rare evidence of neuronophagia
and/or neuronal loss, (2) Moderate: increased numbers
of infiltrating mononuclear cells with occasional neuro-
nophagia and/or neuronal loss, and (3) Severe: abundant
infiltrating mononuclear cells, frequent neuronophagia
and neuronal loss were all present [8, 46, 48].
Immunohistochemistry
DRG sections were deparaffinized with xylene and hy-
drated in a series of graded alcohols. Sections were stained
with antibodies against MAC387 (clone M0747; Dako),
CCR5 (rabbit polyclonal; Novus Biologicals) or CCR2
(clone 7A7; Abcam). Frozen DRG sections were used for
CD137 staining (clone BBK-2). Sections were counter-
stained with hematoxylin, dehydrated, and mounted using
VectaMount permanent mounting medium (Vector Labs).
Tissues were visualized using a Zeiss Axio Imager M1
microscope (Carl Zeiss MicroImaging). Quantification of
the absolute number and percent of positive satellite cells
were performed as previously described [8]. For each ani-
mal, eight non-overlapping fields of view at ×200 magnifi-
cation were quantified by manually counting the number
of positive cells in the field and dividing by the total area
of DRG tissue. The average number of positive cells per
square millimeter was used.
Skin punch and IENFD measurement
Skin punch biopsy specimens with IENF were performed
in all SIV+ animals. Skin punches (3 mm) were taken
serially near the sural innervation site just distal to the
lateral malleolus. Biopsy specimens were taken for each
animal at pre-infection, several time points during infec-
tion, and at necropsy. Biopsy specimens were fixed in
Zamboni’s fixative and processed for dividing into sec-
tions. Sections (50-μm thick) of serial punch skin biopsy
specimens were stained with anti-PGP 9.5, a panaxonal
marker (1:10,000 dilution; ABD Serotec). Nerve fiber
length/volume of epidermis (IENFD) was quantified using
computer software (Space balls program; Microbrightfield
Bioscience) as previously described [8, 49].
BrdU administration
A 30 mg/mL stock of solution was prepared by adding
5-bromo-2-deoxyuridine (BrdU; Sigma-Aldrich) to 1×
phosphate-buffered saline (without Ca2+ and Mg2+) and
heated to 60 °C in a water bath, as previously described
[8, 16, 50]. BrdU was administered as a slow bolus i.v.
injection at a dose of 60 mg BrdU/kg body weight. BrdU
was administered at 8 and 21 days post-infection (DPI)
in animals A01-A07. Additionally, animals A04-A11 re-
ceived BrdU 42, 63 DPI, and 24 h prior to necropsy.
Flow cytometry
Flow cytometric analyses were performed with 100 μl ali-
quots of EDTA-coagulated whole blood. Erythrocytes
were lysed using ImmunoPrep Reagent System (Beckman
Coulter), washed twice with PBS containing 2 % FBS, and
then incubated for 15 min at room temperature with
fluorochrome-conjugated surface antibodies including
anti-HLA-DR-PerCp-Cy5.5 (clone L243), anti-CD16-PE-
Cy7 (clone 3G8), anti-CD3-APC (clone SP34-2), CD8-
APC (clone RPA-T8), anti-CD20-APC (clone 2H7), and
anti-CD14-Pacific blue (clone M5E2). For intracellular
staining, cells were fixed and permeabilized with BD Cyto-
fix/Cytoperm™ buffer (BD Biosciences) for 30 min at room
temperature. Cells were again washed and incubated with
BD Cytoperm Plus™ buffer for 10 min on ice, then washed
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and incubated with DNase (30 mg) for 1 h at 37 °C, and
washed and then stained for intracellular antigen with
anti-BrdU-FITC (clone 3D4; BD Biosciences) and anti-Ki-
67-PE (clone B56; BD Biosciences) for 20 min at room
temperature. Samples were acquired on a BD FACS Aria
(BD Biosciences) and analyzed with Tree Star Flow Jo ver-
sion 9.6. Identification and quantitation of BrdU+ mono-
cytes and CD14+ CD16+ monocytes was performed as
previously described [16].
Preparation of DRG lysate
Frozen lumbar DRG was mechanically homogenized in
Tissue Extraction Reagent I (Invitrogen, Waltham, MA)
containing 1× protease inhibitor (Sigma-Aldrich). For
every 1 g of tissue, 10 mL of lysis buffer was used. Lysate
was centrifuged and supernatant containing protein was
stored at −80 °C. Protein was quantified using a BCA
protein assay kit (Thermo Scientific) according to the
manufacturer’s instructions.
ELISAs
sCD14 and RANTES were quantified in plasma (diluted
1:200 and 1:4; respectively) using ELISA kits (R&D Sys-
tems). sCD163 was quantified in plasma (diluted 1:500)
using an ELISA kit (Trillium Diagnostics). All ELISAs
were carried out according to the manufacturer’s in-
structions and as previously described [16].
Luminex multiplex assays
RANTES, MCP-1, and sCD137 were quantified in DRG
tissue lysates, and MCP-1 and sCD137 were quantified
in plasma using Multiplex Luminex Technology (EMD
Millipore). Non-human Primate Cytokine/Chemokine
Panels 1 and 2 were used according to the manufacturer’s
instructions with the following modifications. For DRG
tissue lysate protein quantification, 10 μg of protein (in
25 μl of lysis buffer) from each sample was loaded onto
the plate. Tissue lysis buffer was used as the matrix for di-
lution of standards and quality control samples. For the
plasma sample analysis, plasma samples were diluted two-
fold in the assay buffer provided. The provided serum
matrix was used for dilution of standards and quality con-
trol samples. All samples were performed in duplicate,
and plates were incubated overnight at 4 °C on a rocker.
Samples were analyzed using MAGPIX System (EMD
Millipore).
Statistical analysis
All statistical analysis was performed using Prism Soft-
ware (Version 5.0d). A Wilcoxon matched-pairs signed-
rank test was used to determine the increase in markers
from pre-infection to necropsy. A Mann-Whitney U
test was used to detect variation between infected and
uninfected samples. ANOVA was used to detect vari-
ance among different pathology groups followed by a
Dunn’s post-test if the ANOVA was significant. Non-
parametric Spearman correlation was used for all corre-
lations. A p value of <0.05 was considered significant
for all tests performed.
Results
Animals used for the study
Eleven rhesus macaques were infected with SIVmac251
and were administered with a CD8-depletion antibody 6, 8,
and 12 DPI in order to rapidly progress to AIDS. All SIV-
infected animals developed mild to severe lumbar DRG
pathology, as well as a loss of IENFD (Table 1, Fig. 1).
Plasma markers of monocyte egress and activation
during SIV infection
Monocyte egress from the bone marrow was measured
by BrdU pulse labeling [16]. We also measured CD14+
Table 1 Animals used in the study
Animal treatment Animal ID Survival (days) % loss of IENFD at necropsy from pre-infection (%) Lumbar DRG pathology
SIV-infected CD8-depleted A01 84 −43.3 Severe (3)
A02 96 −13.0 Mild (1)
A03 106 −74.5 Moderate (2)
A04 89 −36.8 Moderate–severe (2.5)
A05 55 −43.1 Mild–moderate (1.5)
A06 174 −82.5 Severe (3)
A07 146 −51.5 Severe (3)
A08 77 −57.4 Moderate–severe (2.5)
A09 77 −18.4 Moderate (2)
A10 168 −20.4 Mild (1)
A11 97 −51.6a Mild (1)
IENFD intraepidermal nerve fiber density
aPercent change from pre-infection to 63 DPI
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CD16+ monocytes by multicolor flow cytometry and
found that this population of activated monocytes was
expanded during SIV infection (data not shown). We in-
vestigated soluble monocyte activation markers sCD14
(Fig. 2a–c) and sCD163 (Fig. 2d–f ) in plasma and their
correlation to the rate of peripheral monocyte turnover
and the number of CD14+ CD16+activated peripheral
monocytes. Both of these markers increased significantly
in our animals from pre-infection to necropsy using
Wilcoxon matched-pairs signed-rank test (sCD14 p <
0.05; sCD163 p < 0.01). sCD14 was also associated with
the number of BrdU+ monocytes (Fig. 2b, p < 0.05) and
the percent of CD14+ CD16+ monocytes out of the total
number of circulating monocytes (Fig. 2c, p < 0.05).
sCD163 did not significantly correlate to the absolute
number of BrdU+ or CD14+ CD16+ monocytes (Fig. 2e,
f ), in contrast to previously published data where per-
centages and not absolute numbers were examined [16].
Next, we examined the role of RANTES (Fig. 2g–i),
MCP-1 (Fig. 2j–l), and sCD137 (Fig. 2m–o) in monocyte
egress and activation. We identified sCD137 as a novel
signaling protein that may also play an important role in
SIV-DSP pathogenesis because of its role in myelopoi-
esis, monocyte extravasation, and monocyte activation
[37–41]. When we compared pre-infection plasma
concentrations of RANTES, MCP-1, and sCD137 to
necropsy plasma concentrations using the Wilcoxon
matched-pairs signed-rank test, we found that MCP-1
and sCD137 both increased significantly during infection
(MCP-1, p < 0.001; sCD137, p < 0.01). RANTES was not
increased significantly during infection, but it correlated
with the percent of activated CD14+ CD16+ monocytes
in circulation at matched time points (p < 0.05, Fig. 2i).
Additionally, necropsy plasma concentrations of RANTES
and MCP-1 were associated with more severe DRG path-
ology (p < 0.05, Fig. 2g, j). MCP-1 was also associated with
monocyte egress from the bone marrow (p < 0.001, Fig. 2k)
and with CD14+ CD16+ monocytes (p < 0.05, Fig. 2l).
sCD137 did not significantly correlate with either BrdU+
or CD14+ CD16+ blood monocytes (Fig. 2n, o). These
data suggest that the rate of monocyte activation and
egress from the bone marrow is likely controlled by sev-
eral soluble factors. Because of this complexity and likely
redundancy of pathways, suppressing elevated rates of
myelopoiesis is unlikely to be a successful pharmacologic
target. In addition, we found that three out of five of our
examined proteins to be correlated with the percent of
CD14+ CD16+ monocytes, which are typically considered
to be the most activated monocyte population, but it is
unclear if this population of monocytes is activated by
these proteins or producing these signaling factors.
Correlates of reduced IENFD
All 11 SIV-infected animals used in this study had a de-
crease in IENFD at necropsy, compared to pre-infection,
as well as varying degrees of DRG pathology ranging
from mild (score of 1) to severe (score of 3) (Table 1). A
greater percent loss of IENFD from pre-infection to nec-
ropsy was associated with a higher DRG pathology score
(Fig. 3; p < 0.05). These data show that pathology of
DRG and loss of IENFD are linked in severity.
We hypothesized that monocyte activation and che-
mokines responsible for monocyte traffic to the DRG
may facilitate neurodegeneration resulting in a reduced
density of nerve fibers in the periphery. To test this, we
correlated sCD14 (Fig. 4a), sCD163 (Fig. 4b), RANTES
(Fig. 4c), MCP-1 (Fig. 4d), and sCD137 (Fig. 4e) with ab-
solute IENFD at matched time points. sCD163 (p < 0.0001)
and RANTES (p < 0.0001) in plasma negatively correlated
with absolute IENFD values. No significant correlation was
found for sCD14, MCP-1, and sCD137. Thus, increased
monocyte activation and possibly chemotaxis are involved
in the dying-back of axons during SIV infection.
Elevated monocyte chemoattractants in DRG tissue
during SIV infection
Next, we sought to investigate which chemokines are as-
sociated with monocyte traffic to the DRG. We have
previously shown that an influx of mononuclear cells to
A B
DC
Fig. 1 Dorsal root ganglia pathology. a DRG with mild focal
satellitosis, which is defined as increased numbers of cells around a
neuronal cell body (arrow). b DRG with moderate inflammation that
has replaced a few ganglion cells (arrow) with an increase in satellite
cells (c) DRG with inflammation associated with a degenerate
ganglion cell (arrow). Note the cells encroaching around the outside
of the ganglion indicative of neuronophagia, a precursor lesion to
the development of a Nageotte nodule. d DRG with a Nageotte
nodule, focal proliferation of satellite cells that completely replace
foci of neuronal cell loss (arrow)






















































































































































































































































































































































































































































































Fig. 2 Correlates of plasma markers of monocyte activation and monocyte chemoattractants. sCD14 (a–c), sCD163 (d–f), RANTES (g–i), MCP-1
(j–l), and sCD137 (m–o) were measured in plasma at multiple time points throughout infection. a, d, g, j, and m Pre-infection and necropsy
plasma concentrations were compared using a Wilcoxon matched-pairs signed-rank test. Necropsy plasma concentrations were grouped
according to the lumbar DRG pathology and compared using a Kruskal-Wallis test. The number of BrdU+ monocytes in blood (b, e, h, k, n)
and the percent of CD14+ CD16+ monocytes of the total monocyte population (c, f, i, l, o) was determined by flow cytometry and correlated
to the plasma soluble protein concentrations at matched time points. A Spearman correlation test was used for all correlations. p value of <0.05 was
considered significant
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the DRG during SIV infection is associated with severe
tissue pathology [8]. Thus, we hypothesized that mono-
cyte chemoattractants will be elevated in DRG tissue.
Whole DRG tissue, consisting of neurons, satellite cells,
and vasculature, were homogenized, and proteins were
extracted and analyzed by multiplex assay. There was no
detectable difference in RANTES between uninfected
and infected DRG tissues, but there was a trend for ele-
vated RANTES in SIV+ DRG with more severe path-
ology, although this did not reach statistical significance
(Fig. 5a). MCP-1 was elevated in SIV+ DRG compared
to uninfected control tissue (Fig. 5b; p < 0.05). sCD137
was only above the detection level in the three DRG ex-
amined with severe pathology (Fig. 5c; ANOVA < 0.001).
To determine if the levels of these chemoattractants in
DRGs correlated with the absolute number of MAC387+
recently recruited monocytes in DRGs, we correlated the
protein concentrations of RANTES, MCP-1, and sCD137
with the number of MAC387+ monocytes in tissue deter-
mined by immunohistochemistry. No significant correl-
ation was found for RANTES or MCP-1 for recruitment
of MAC387+ cells (Fig. 5d, e). The amount of sCD137 in
DRGs positively correlated with the number of MAC387+
cells in matched DRG tissue (Fig. 5f, p < 0.05). These
results point to a potential role in sCD137 recruiting
MAC387+ monocytes to DRG tissue and facilitating se-
vere tissue damage. Alternatively, MAC387+ cells could
be releasing sCD137.
The chemotactic role of RANTES and MCP-1 is well
established. MAC387+ cells in the brain of SIV+ ma-
caques are CCR2−. Instead, CCR2 was expressed on
perivascular macrophages [51]. Thus, we sought to dem-
onstrate the likely role RANTES and MCP-1 play in
recruiting monocytes to DRG. We found increased num-
bers of CCR5+ (Fig. 6a–c) and CCR2+ (Fig. 6d–f ) satel-
lite cells in infected tissue (Fig. 6e, h) compared to
uninfected (Fig. 6d, g) controls. The increase of CCR5+
and CCR2+ with SIV infection in DRG was quantitated
and found to be statistically significant (Fig. 6c, f; p <
0.05 and p < 0.05).
sCD137 is generated by alternative splicing [44].
Membrane-bound CD137 is expressed on a wide range of
cell types, including monocytes and expression of CD137
facilitates monocyte extravasation into tissue [37, 39, 52].
Thus, we chose to examine membrane-bound CD137 ex-
pression on satellite cells in DRGs of SIV− (Fig. 6g) and









































Fig. 3 Severe DRG pathology was correlated to a greater loss of
IENFD. Lumbar DRG (LDRG) pathology was scored on a scale of 1.0
(mild) to 3.0 (severe). IENFD was measured at pre-infection and
necropsy, and the percent change was calculated by dividing the
difference in IENFD from pre-infection to necropsy by the pre-
infection value and multiplying by 100. Percent change of IENFD
was correlated to LDRG pathology using a Spearman correlation











































































































Fig. 4 sCD163 and RANTES in plasma negatively correlated to IENFD.
IENFD was measured at multiple time points throughout infection in all
SIV+ animals. sCD14 (a), sCD163 (b), RANTES (c), MCP-1 (d), and sCD137
(e) in plasma were correlated to IENFD at matched time points using a
Spearman correlation test. p value of <0.05 was considered significant
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CD137+ cells in SIV+ DRG tissue correlates to tissue
pathology (Fig. 6i, ANOVA < 0.05). Because CD137 is not
unique to myeloid cells, we performed double immuno-
histochemistry stains. We found that 16.1 % of CD137+
cells were T cells (CD3+) and 33.5 % of CD137+ cells
expressed CD68, a pan-macrophage marker (data not
shown). However, because MAC387+ macrophages do
not co-express CD68, we suspect the remainder of the
CD137+ cells in DRG tissue to be MAC387+ macro-
phages. However, the MAC387 and CD137 antibodies
required different tissue preparation for immunohisto-
chemistry and were incompatible with each other to per-
form a double stain. Despite this technical pitfall, the
correlation of sCD137 to MAC387+ satellite cells in DRG
and increased CD137+ satellite cells in DRG with severe
pathology highlight a novel potential role of CD137 signal-
ing during SIV infection and DSP pathogenesis.
Discussion
HIV-PN continues to be a major co-morbidity of HIV
infection despite reduction of plasma viral load. Cur-
rently, there is no successful treatment for HIV-PN, and
thus, understanding the underlying mechanism of neur-
onal damage is of utmost importance to improve patient
quality of life. There is increasing evidence that chronic
monocyte/macrophage activation plays a key role in
the pathogenesis of HIV/SIV-PN. Animal models of
HIV-PN and studies in humans have shown an increase
in myeloid cell activation in the DRG and spinal col-
umn, as well as a loss of IENFD [3, 8, 53–55]. We have
previously demonstrated that increased BrdU+ mono-
cyte traffic to the DRG is associated with severe DRG
pathology [8].
Numerous studies have examined the expansion of the
CD14+ CD16+ monocyte population during HIV/SIV
infection and the link to inflammatory co-morbidities
[16, 56, 57]. We have also shown that the rate of mono-
cyte egress from the bone marrow, measured by BrdU
pulse labeling, is correlated to faster disease progression
to AIDS [16]. To investigate the systemic inflammation
that is causing neuronal damage, both in the DRG and
in the extremities, we examined five soluble proteins in
plasma, which are associated with monocyte activation
and traffic. Here, we found that plasma sCD14 and
MCP-1 were correlated to the number of BrdU+ mono-
cytes in blood. We also found that sCD14, RANTES,
and MCP-1 were correlated to the percent of CD14+
CD16+ monocytes out of total blood monocytes. CD14+
CD16+ monocytes are an activated population of mono-
cytes that highly express CCR2, the receptor for MCP-1,
and CD163 [58, 59]. Elevated levels of RANTES and





























































































































































































Fig. 5 RANTES, MCP-1, and sCD137 protein levels in DRG tissue. RANTES (a), MCP-1 (b), and sCD137 (c) were detected by Luminex multiplex assay
in DRG tissue lysate. Differences in protein concentrations in SIV– and SIV+ DRG tissue were analyzed using a Mann-Whitney test. SIV+ DRGs were
grouped according to the tissue pathology. Differences between SIV+ tissue pathology groups were analyzed using a Kruskal-Wallis test, followed
by a Dunn’s post-test. The amount of RANTES (d), MCP-1 (e), and sCD137 (f) in DRG tissue lysate were correlated to the number of MAC387+
cells/mm2 determined by immunohistochemistry using a Spearman correlation test. p value of <0.05 was considered significant
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severe DRG pathology, compared to mild pathology.
These findings confirm these soluble factors in plasma
are associated with monocyte activation and traffic dur-
ing SIV-PN.
Because the blood-nerve barrier is more promiscuous
(or leakier) than the blood-brain barrier [60], we as-
sumed that neurons were exposed to all proteins found
in plasma. Several inflammatory cytokines have been
found to be neurotoxic in vitro [61, 62], but this direct
causation is difficult to prove in vivo. We found a signifi-
cant inverse correlation between sCD163 and IENFD.
Thus, sCD163 may be useful as a plasma biomarker of
IENFD loss in HIV+ patients. While sCD163 and sCD14
are both markers of monocyte activation, they are shed
by different mechanisms. CD163 is highly expressed on
M2-polarized macrophages and CD14+ CD16+ mono-
cytes, while CD14 is present on all populations of mono-
cytes and is shed in the setting of non-specific activation
[63] and CD163 is shed due to cell-surface TLR activa-
tion [64]. Plasma RANTES/CCL5 also correlated to a re-
duction in IENFD. Other studies have demonstrated that
the supernatant of macrophages exposed to gp120, pre-
sumably containing proteins such as sCD163 and
RANTES, is capable of damaging neurons in vitro [61].
Even though sCD163 and RANTES strongly correlated
to a reduction of IENFD, the dying back of axons is
likely caused by several signals.
Here, we found a link between the severity of DRG
pathology and a greater loss of small nerve fiber density
in the footpad. It is unknown if a loss of IENFD comes
before damage to the DRG or vice versa. One study sug-
gested that damage to the DRG preceded altered func-
tional activity of nerve fibers in the periphery [65].
However, we have observed an early loss of IENFD (as
early as 8 DPI) and minimal DRG pathology in animals
sacrificed at 21 DPI (data not shown). Regardless, we
found an association between pathology at the DRG and
in the footpad, suggesting a relay of signals from one re-
gion to the other, or perhaps systemic neuroinflamma-
tory/neurotoxic proteins that facilitate damage to both
regions simultaneously.
To investigate the local signals in the DRG responsible
for monocyte traffic, we analyzed DRG tissue homogen-
ate using a multiplex assay that allowed for quantifica-
tion of many proteins with a small amount of tissue
homogenate available. The limitation of this method is
that it is unknown which cell types are producing the
proteins that were detected. Endothelial cells, neurons,
Fig. 6 CCR5, CCR2, and CD137 expression on DRG satellite cells. The number of CCR5 (a–c), CCR2 (d–f), and CD137 (g–i) positive satellite cells in
DRG tissue was determined by immunohistochemistry in uninfected (a, d, g) and SIV-infected animals (b, e, h). Arrows show CCR5+ cells in SIV+
DRG tissue. For each animal, eight non-overlapping fields of view at ×200 magnification were quantified by manually counting the number of
positive cells in the field and dividing by the total area of DRG tissue. The average number of positive cells per square millimeter is plotted for
each animal (c, f, i). Analysis in SIV− and SIV+ DRG tissue was determined using a Mann-Whitney test. SIV+ DRGs were grouped according to the
tissue pathology. Differences between pathology groups determined using a Kruskal-Wallis test, followed by a Dunn’s post-test. p value of <0.05
was considered significant
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Schwann cells, and immune cells (including macro-
phages and T cells) in the DRG are all capable of secret-
ing cytokines and chemokines. However, this method still
affords us the opportunity to investigate the local signals
responsible for monocyte traffic and neuronal damage at
the DRG. We found that MCP-1 in DRG tissue was sig-
nificantly increased in DRG from SIV+ animals compared
to uninfected control tissue. Because MCP-1 is a potent
monocyte chemoattractant and is produced by activated
macrophages, it is likely that MCP-1 is partially respon-
sible for increased monocyte traffic to the DRG.
In addition to the proteins we reported on in detail
here, we also investigated other known monocyte che-
moattractants, both in the DRG and in plasma. We did
not find a significant increase in MIP-1α, MIP-1β, and
MIP-3α in plasma nor were these proteins elevated in
SIV+ DRG tissue lysate. In fact, these proteins were
below detection level for many of the DRG samples
tested. However, monocyte activation and traffic is a
complex process, likely to be controlled by several sig-
naling molecules that were not included on the two
cytokine/chemokine panels we utilized.
sCD137/CD137 (formally called 4-1BB or tumor necro-
sis factor receptor superfamily member 9 (TNFRSF9)) has
not been extensively studied in the context of monocyte
activation during HIV infection, although its known func-
tions in other diseases are relevant to HIV pathogenesis.
Here, CD137 was found to potentially play a role in SIV-
DSP pathogenesis. The soluble form of CD137 (sCD137)
is generated by alternative splicing and was found to sig-
nificantly increase in plasma from pre-infection to ter-
minal AIDS. Additionally, sCD137 was only detectable in
DRG lysate with severe pathology, and it correlated with
the number of MAC387+ cells in DRG tissue. CD137 is
expressed on a wide range of cell types, although most of
the research on this protein focuses on T cell activation
[36–38]. However, CD137 signaling has been shown to
play a role in myelopoiesis, monocyte activation, and
monocyte extravasation into inflamed tissue [37, 38, 41].
The known roles of CD137 in regard to monocyte activity
are also highly deregulated during HIV/SIV infection.
Additional research needs to be conducted in order to fur-
ther define the role of CD137 signaling in HIV/SIV dis-
ease progression. CD137 activation, through the use of
agnostic monoclonal antibodies, has proven to have po-
tential for cancer treatment by stimulating the immune
system to target cancer cells [66]. Blocking CD137 may
ameliorate chronic immune activation seen during HIV/
SIV infection.
Conclusions
Our findings presented here demonstrate the complexity
of the neuro-immune interaction that occurs during the
pathogenesis of SIV-DSP. Neurons are capable of
producing cytokines and express cytokine receptors.
Stimulation through these receptors has been shown to
modulate pain signaling [33, 62]. However, targeting a
single cytokine or a receptor is likely not to reverse or
prevent nerve damage due to redundancy of immune
signaling. No single protein that was investigated in this
study was found to associate with all the factors we
know to be important in nerve damage during SIV infec-
tion. However, sCD163 and RANTES were identified as
potential biomarkers for loss of IENFD. Additionally, el-
evated sCD137 in DRG tissue lysate was found to be as-
sociated with MAC387+ cell recruitment and severe
pathology. The role of CD137 signaling during SIV-PN
pathogenesis warrants further investigation. Future stud-
ies should focus on blockade of multiple signals which
may dampen monocyte activation and traffic to the DRG
and thus prevent a loss of IENFD and DRG damage.
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